<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81569">
  <stage>Registered</stage>
  <submitdate>28/08/2006</submitdate>
  <approvaldate>29/08/2006</approvaldate>
  <actrnumber>ACTRN12606000380594</actrnumber>
  <trial_identification>
    <studytitle>An Open Label, Dose Titration Study Of Sevelamer Carbonate Dosed Three Times A Day In Hyperphosphatemic Chronic Kidney Disease (CKD) Patients Not On Dialysis</studytitle>
    <scientifictitle>An Open Label, Dose Titration Study of Sevelamer Carbonate dosed Three Times A Day in the control of phosphorus levels in Hyperphosphatemic Chronic Kidney Disease Patients Not On Dialysis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Hyperphosphatemia in CKD Patients not on Dialysis</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study will test an 8-week treatment course of the investigational drug Sevelamer Carbonate, at doses from 4.8g up to 12g orally daily, in patients with Hyperphosphatemic CKD not on dialysis.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The change from baseline (Day 0) to Day 56/early termination (ET) in serum phosphorus.</outcome>
      <timepoint>At baseline (day 0) and day 56</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum calcium-phosphorus product</outcome>
      <timepoint>Baseline and study day 56.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum lipid profile</outcome>
      <timepoint>Baseline and study day 56.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent responders</outcome>
      <timepoint>Baseline and study day 56.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>CKD patients not on dialysis; documented hyperphosphatemia without the use of a phosphate binder or after washout from current phosphate binder; signed informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known hypersensitivity to the investigational product or any constituents of the study drug; active bowel obstruction, dysphagia, swallowing disorder or severe gastrointestinal (GI) motility disorders; in the opinion of the investigator, patient has poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, HIV infection, or any clinically significant unstable medical condition; pregnant or breast-feeding; evidence of active malignancy except for basal cell carcinoma of the skin; unable to comply with the requirements of the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genzyme Corporation, USA</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Genzyme Corporation</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Novotech (Australia) Pty Ltd</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jeremy Heaton, MD</name>
      <address>Medical Director, Renal
Genzyme Europe Research
310 Cambridge Science Park
Milton Road, Cambridge</address>
      <phone>+44 1223 394 053</phone>
      <fax />
      <email>jeremy.heaton@genzyme.com</email>
      <country>United Kingdom</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Manjula Kishoon</name>
      <address>Novotech (Australia) Pty Ltd
19 Harris Street
Pyrmont NSW 2009</address>
      <phone>+61 2 9518 9600</phone>
      <fax />
      <email>manjula.kishoon@novotech-cro.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>